title: Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?
abstract: Multidrug-resistant Gram-negative bacteria continue to pose a threat, with many infections caused by these pathogens being virtually untreatable. A number of new antibacterial agents are in late stage clinical development to treat these infections. Drugs in known classes such as new quinolones, aminoglycosides, tetracyclines, and β-lactams have been designed to evade many of the known resistance mechanisms, whereas newer drug classes include novel β-lactamase inhibitors in combination with new or approved β-lactams, and a peptidomimetic that have entered full clinical development. The establishment of public-private partnerships and an increase in pharmaceutical interest in antibacterial R&D are encouraging signs for the future.
authors.affiliation: Basilea Pharmaceutica International Ltd, Basel, Switzerland.
authors.forename: Malcolm G P
authors.initials: MG
authors.lastname: Page
authors.affiliation: Indiana University, Simon Hall, 212 S. Hawthorne Drive, Bloomington, IN, USA. Electronic address: karbush@indiana.edu.
authors.forename: Karen
authors.initials: K
authors.lastname: Bush
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D055808:Drug Discovery; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D015507:Drugs, Investigational / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006801:Humans; D055818:Public-Private Sector Partnerships
chemical_list: D000900:Anti-Bacterial Agents; D015507:Drugs, Investigational